This is a summary of the European public assessment report (EPAR) for Colobreathe. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Colobreathe.
Therapeutic Indication
Colobreathe is indicated for the management of chronic pulmonary infections due to *Pseudomonas aeruginosa* in patients with cystic fibrosis (CF) aged six years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Therapeutic Area (MeSH)
ATC Code
J01XB01
ATC Item
N/A
Pharmacotherapeutic Group
Antibacterials for systemic use
Active Substance (Summary)
INN / Common Names
EMA Name
Colobreathe
Medicine Name
Colobreathe
Aliases
N/ANo risk management plan link.
